NCT00401570 - A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Pancreatic Cancer

Interventions

DRUG

Volociximab

Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.

DRUG

Gemcitabine

Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment

Trial Locations (6)

Site Reference ID/Investigator# 70538, Pittsburgh

Site Reference ID/Investigator# 70537, Nashville

Site Reference ID/Investigator# 70534, Glasgow

Site Reference ID/Investigator# 70533, Leeds

Site Reference ID/Investigator# 70536, Manchester

Site Reference ID/Investigator# 70535, Northwood

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY